Pharmaceutical Research and Manufacturers of America reported Wednesday that 444 drugs intended to treat neurological disorders are in clinical development or being reviewed by the FDA. "Despite the incredible complexity of neurological disorders, biopharmaceutical scientists have delivered significant advances for patients in recent years, including new medicines for multiple sclerosis and Huntington's diseases," said John J. Castellani, PhRMA's president and CEO.

Full Story:
Drug Store News

Related Summaries